Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Gastric cancer; Renal cell carcinoma
  • Phase I/II Solid tumours
  • Phase I Glioblastoma
  • No development reported Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Mar 2018 Bristol-Myers Squibb plans a phase I/II trial for Cancer (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/Unresectable) in April 2018 (NCT03459222)
  • 13 Feb 2018 Bristol-Myers Squibb initiates enrolment in the phase I ADVISE trial for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03335540)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top